Summary (tl;dr)

Eli Lilly and Company is trending due to exceptionally strong first-quarter 2026 financial results, driven by booming sales of its GLP-1 drugs Mounjaro and Zepbound, and the significant U.S. FDA approval of its new oral GLP-1 obesity medication, Foundayo (orforglipron). The company has also raised its full-year guidance and is actively advancing its Alzheimer's disease research.

Essential Background

In recent years, Eli Lilly has emerged as a leader in the treatment of diabetes and obesity with its injectable GLP-1 (glucagon-like peptide-1) receptor agonist medications, Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (tirzepatide) for weight loss. These drugs have seen rapidly increasing demand globally due to their efficacy in blood sugar management and significant weight reduction. Additionally, Eli Lilly's Alzheimer's drug, Kisunla (donanemab), was approved for early symptomatic Alzheimer's disease in previous years, marking its presence in another critical therapeutic area.

The Full Story

Eli Lilly reported a robust start to 2026, with first-quarter revenues surging 56% to $19.8 billion compared to the same period in 2025, primarily fueled by a 65% increase in volume, despite a 13% decrease from lower realized prices. This impressive growth was largely driven by Mounjaro, which generated $8.66 billion in global sales, and Zepbound, contributing $4.16 billion in U.S. revenue. The company's reported earnings per share (EPS) jumped by 170% to $8.26.

A pivotal development was the U.S. FDA approval in April 2026 of Foundayo (orforglipron), Eli Lilly's new once-daily oral GLP-1 pill for adults with obesity or overweight with weight-related medical problems. Foundayo is notable as the only approved GLP-1 pill that can be taken at any time of day, without food and water restrictions, making it a convenient option for patients and a "paradigm shift" in the obesity treatment market. Analysts project blockbuster potential for Foundayo. The company has also increased its full-year 2026 revenue guidance to a range of $82.0 billion to $85.0 billion.

Furthermore, Eli Lilly is preparing to present 16 research abstracts at the 2026 Alzheimer's Association International Conference in London from July 12-15, including new data on its Alzheimer's treatment Kisunla (donanemab-azbt) and diagnostic methods. The company's commitment to expanding access to its obesity medicines is also evident, with agreements allowing Medicare beneficiaries to pay as little as $50 per month for Zepbound and Foundayo. Globally, Mounjaro has also been added to China's National Reimbursed Drug List, contributing to its international sales growth.

However, the pharmaceutical landscape is dynamic, with Swiss pharmaceutical company Sandoz requesting FDA review for generic versions of tirzepatide (Mounjaro and Zepbound), although Eli Lilly's patents in the U.S. are valid until 2036. Eli Lilly is also in discussions with UK ministers regarding drug pricing to unpause planned investments.

Why It Matters

Eli Lilly's strong performance and pipeline developments are highly significant for the pharmaceutical industry and public health. The continued dominance of Mounjaro and Zepbound underscores the immense demand for effective diabetes and obesity treatments, positioning Lilly as a market leader with a market capitalization exceeding $1 trillion. The approval of Foundayo is particularly impactful as it broadens access to GLP-1 therapies through a convenient oral form, potentially reaching a wider patient population and reshaping the competitive landscape for weight management drugs.

The company's ongoing research in Alzheimer's disease with Kisunla and forthcoming data presentations highlight its dedication to addressing critical unmet medical needs in neuroscience. Efforts to make medications more affordable through programs like Lilly Direct and agreements with Medicare could also improve patient access, although pricing discussions in international markets like the UK reflect ongoing global challenges in drug affordability and pharmaceutical investment. The potential for generic competition for its blockbuster GLP-1 drugs, while still years away in the U.S., signals future shifts in market dynamics and pricing pressures.

Geographic Location

• Indianapolis, Marion County, Indiana, United States (Eli Lilly and Company headquarters, financial announcements)
• United States (FDA approvals for Foundayo and Mounjaro/Zepbound, Medicare program agreements)
• London, England, United Kingdom (Alzheimer's Association International Conference, discussions on drug pricing)
• China (Mounjaro added to National Reimbursed Drug List)